SSG
PRAX icon

Summit Securities Group’s Praxis Precision Medicines PRAX Stock Holding History

Summit Securities Group’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-164
Closed -$8.69K – 1201
2025
Q3 		$8.69K Buy
+164
New +$7.95K ﹤0.01% 880
2025
Q2 		– Sell
-40
Closed -$1.51K – 1349
2025
Q1 		$1.51K Buy
+40
New +$2.5K ﹤0.01% 682

Other funds holding PRAX

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Summit Securities Group's PRAX Position: Q4 2025 in Review

Summit Securities Group sold out of Praxis Precision Medicines (PRAX) in Q4 2025, closing a stake of 164 shares — an estimated $8.69K sold.

Summit Securities Group first reported a position in PRAX in Q1 2025 and held it in 2 quarters. The position peaked at $8.69K in Q3 2025. 250 funds tracked by Wall St. Rank hold PRAX as of Q4 2025.

  • Summit Securities Group reported no remaining Praxis Precision Medicines position as of Q4 2025 after selling out during the quarter.
  • Summit Securities Group sold 164 Praxis Precision Medicines shares in Q4 2025, an estimated $8.69K.
  • Summit Securities Group first reported a position in Praxis Precision Medicines in Q1 2025 and held it in 2 quarters.
  • Summit Securities Group's Praxis Precision Medicines position peaked at $8.69K in Q3 2025.
  • 250 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q4 2025.

Based on Summit Securities Group's 13F filing for Q4 2025, filed 17 Feb 2026.